Jefferies Financial Group Inc. Sells 40,875 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Jefferies Financial Group Inc. cut its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.4% in the 4th quarter, HoldingsChannel reports. The firm owned 45,304 shares of the specialty pharmaceutical company’s stock after selling 40,875 shares during the period. Jefferies Financial Group Inc.’s holdings in Supernus Pharmaceuticals were worth $2,252,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Hantz Financial Services Inc. lifted its position in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 281 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $49,000. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the last quarter. Global Retirement Partners LLC lifted its position in Supernus Pharmaceuticals by 532.4% during the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 1,182 shares during the last quarter. Finally, Vestcor Inc bought a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $67,000.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $47.77 on Wednesday. The company has a market capitalization of $2.77 billion, a PE ratio of -93.67, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. Supernus Pharmaceuticals, Inc. has a one year low of $30.83 and a one year high of $59.68. The company’s 50 day moving average price is $49.91 and its two-hundred day moving average price is $49.58.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, March 16th. The shares were sold at an average price of $50.28, for a total value of $2,514,000.00. Following the transaction, the vice president directly owned 17,044 shares of the company’s stock, valued at $856,972.32. The trade was a 74.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the completion of the transaction, the director directly owned 28,159 shares in the company, valued at approximately $1,512,419.89. The trade was a 26.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 116,406 shares of company stock valued at $5,911,086. 8.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.